Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
Clinical trial NCT06495515 · UNKNOWN
Trial details
- NCT number
- NCT06495515
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2025-07-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.